Letter from the Editor

Dear Colleagues,

Thank you for your interest in this edition of Medicom’s Conference Report covering the European Academy of Neurology’s 2025 Congress, held in Helsinki, Finland. This year’s meeting addressed a wide array of topics, from innovative applications of adaptive deep brain stimulation in Parkinson’s disease to novel treatment strategies in migraine, myasthenia gravis, and neuromuscular disorders. 

In the following pages, you will find new data on adaptive deep brain stimulation for Parkinson’s disease in routine clinical care, important evidence that liraglutide markedly decreases monthly migraine days independent of weight loss, and findings from a multicentre real-world cohort study comparing early versus delayed add-on therapy in generalised myasthenia gravis. In addition, results from the Phase 3 PROPEL study in late-onset Pompe disease provide valuable insights into long-term management of this rare neuromuscular disorder, while early reports of virus-specific T-cell therapy for progressive multifocal leukoencephalopathy and CD19 CAR-T cell therapy in refractory autoimmune neuropathies highlight the transformative potential of immune-based treatments in neurology. 

I hope you find the summaries included informative, balanced, and inspiring, as we look forward to the great promise of scientific innovation that will improve outcomes for patients suffering from neurological diseases. Thank you for your continued interest in our coverage of the latest developments in neurology. 

Sincerely, 

 Prof. Hans-Peter Hartung 

 

Biography

Prof. Hartung is currently Professor of Neurology at Heinrich-Heine-University Düsseldorf, Honorary Professor at Brain and Mind Center, University of Sydney, Visiting Professor at Medical University Vienna and Palacky University Olomouc. He was chairman of the Department of Neurology, Heinrich-Heine-University Düsseldorf from 2001-2020, director of the Center for Neurology and Neuropsychiatry from 2012-2020 and director of the Department of Conservative Medicine from 2012-2019.

Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies, development of new immunological, neuroprotective and neural repair promoting strategies. He has (co-)authored more than 950 articles in peer-reviewed journals and 100 book chapters. He has been involved as member of the Steering Committee in numerous international multicentre therapeutic phase 2 and 3 trials in multiple sclerosis, Guillain-Barré Syndrome and CIDP.

He was President of ECTRIMS and has served/ serves amongst others on the executive boards of the European Charcot Foundation, the European Neurological Society, and the International Multiple Sclerosis Cognition Society (IMSCOGS). He is/was also member of the Editorial Board of a number of international journals. Prof. Hartung is a Fellow of the AAN and EAN, and has been chair/ member of the management group of the EAN scientific panels on general neurology and multiple sclerosis. He is Corresponding and Honorary Fellow of several international societies.

Conflict of Interest Statement: Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, Teva, TG Therapeutics, and Viela Bio, with approval by the Rector of Heinrich-Heine University.



Posted on 3 September 2025